Dupont Capital Management’s Insys Therapeutics, Inc. INSY Stock Holding History

Dupont Capital Management’s Portfolio INSY Stock Details INSY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-36,606	Closed	-$463K	–	1011
2017 Q2	$463K	Hold	36,606	–	–	0.01%	703
2017 Q1	$385K	Hold	36,606	–	–	0.01%	753
2016 Q4	$337K	Hold	36,606	–	–	0.01%	758
2016 Q3	$432K	Buy	+36,606	New	+$556K	0.01%	583
2016 Q1	–	Sell	-42,427	Closed	-$1.22M	–	722
2015 Q4	$1.22M	Sell	42,427 -8,670	-17%	-$240K	0.03%	437
2015 Q3	$1.45M	Sell	51,097 -52,071	-50%	-$1.92M	0.04%	394
2015 Q2	$3.71M	Sell	103,168 -19,790	-16%	-$616K	0.08%	245
2015 Q1	$3.57M	Buy	122,958 +65,220	+113%	+$1.72M	0.07%	264
2014 Q4	$1.22M	Hold	57,738	–	–	0.02%	443
2014 Q3	$1.12M	Buy	57,738 +22,600	+64%	+$355K	0.02%	441
2014 Q2	$549K	Sell	35,138 -2	-0%	-$32	0.01%	573
2014 Q1	$728K	Sell	35,140 -18,929	-35%	-$375K	0.01%	552
2013 Q4	$698K	Sell	54,069 -83,583	-61%	-$1.16M	0.01%	541
2013 Q3	$1.6M	Buy	+137,652	New	+$1.13M	0.03%	419

Other funds holding INSY

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

FHAM

Folger Hill Asset Management New York $16.5M AUM 19.96% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Dupont Capital Management's INSY Position: Q3 2017 in Review

Dupont Capital Management sold out of Insys Therapeutics, Inc. (INSY) in Q3 2017, closing a stake of 36,606 shares — an estimated $463K sold.

Dupont Capital Management first reported a position in INSY in Q3 2013 and held it in 14 quarters. The position peaked at $3.71M in Q2 2015. 116 funds tracked by Wall St. Rank hold INSY as of Q3 2017.

Dupont Capital Management reported no remaining Insys Therapeutics, Inc. position as of Q3 2017 after selling out during the quarter.
Dupont Capital Management sold 36,606 Insys Therapeutics, Inc. shares in Q3 2017, an estimated $463K.
Dupont Capital Management first reported a position in Insys Therapeutics, Inc. in Q3 2013 and held it in 14 quarters.
Dupont Capital Management's Insys Therapeutics, Inc. position peaked at $3.71M in Q2 2015.
116 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q3 2017.

Based on Dupont Capital Management's 13F filing for Q3 2017, filed 31 Oct 2017.